Hyloris Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Hyloris Pharmaceuticals şirketinin toplam hissedar öz sermayesi €34.7M ve toplam borcu €120.0K olup, bu da borç-öz sermaye oranını 0.3% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla €45.4M ve €10.8M dir.

Anahtar bilgiler

0.3%

Borç/özkaynak oranı

€120.00k

Borç

Faiz karşılama oranı	n/a
Nakit	€27.96m
Eşitlik	€34.66m
Toplam yükümlülükler	€10.78m
Toplam varlıklar	€45.44m

Son finansal sağlık güncellemeleri

Here's Why We're Not Too Worried About Hyloris Pharmaceuticals' (EBR:HYL) Cash Burn Situation

Aug 04

Hyloris Pharmaceuticals (EBR:HYL) Is In A Strong Position To Grow Its Business

Dec 28

Recent updates

Here's Why We're Not Too Worried About Hyloris Pharmaceuticals' (EBR:HYL) Cash Burn Situation

Aug 04

Hyloris Pharmaceuticals (EBR:HYL) Is In A Strong Position To Grow Its Business

Dec 28

Do Institutions Own Hyloris Pharmaceuticals SA (EBR:HYL) Shares?

Mar 08

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: HYL 'nin kısa vadeli varlıkları ( €32.8M ) kısa vadeli yükümlülüklerini ( €8.8M ) aşıyor.

Uzun Vadeli Yükümlülükler: HYL şirketinin kısa vadeli varlıkları ( €32.8M ) uzun vadeli yükümlülüklerini ( €1.9M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: HYL şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: HYL şirketinin 5 yıl önce negatif özkaynağı vardı, ancak şu anda pozitif ve dolayısıyla iyileşme kaydetti.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: HYL şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: HYL serbest nakit akışı her yıl % 17.3 1.1 yıl yetecek nakit akışına sahip olacaktır.

Hyloris Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Here's Why We're Not Too Worried About Hyloris Pharmaceuticals' (EBR:HYL) Cash Burn Situation

Hyloris Pharmaceuticals (EBR:HYL) Is In A Strong Position To Grow Its Business

Recent updates

First half 2024 earnings released: €0.12 loss per share (vs €0.20 loss in 1H 2023)

Hyloris Pharmaceuticals SA to Report Fiscal Year 2024 Results on Mar 20, 2025

Hyloris Pharmaceuticals SA to Report Fiscal Year 2024 Final Results on Apr 30, 2025

New major risk - Revenue and earnings growth

No longer forecast to breakeven

New major risk - Revenue and earnings growth

No longer forecast to breakeven

Here's Why We're Not Too Worried About Hyloris Pharmaceuticals' (EBR:HYL) Cash Burn Situation

Price target decreased by 7.5% to €19.10

Insufficient new directors

Consensus revenue estimates decrease by 14%, EPS upgraded

Price target increased by 8.3% to €21.55

Consensus revenue estimates decrease by 50%

Price target increased by 7.3% to €20.65

Hyloris Pharmaceuticals SA to Report First Half, 2024 Results on Sep 05, 2024

Full year 2023 earnings released

Hyloris Pharmaceuticals SA Enrolls First Patient in Phase 3 Clinical Trial for Its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental Procedures

Hyloris Pharmaceuticals SA Announces Positive Results for the Phase 2 Trial of Miconazole Domiphen-Bromide (MCZ-DB) in Patients with Acute Vulvovaginal Candidiasis

Hyloris Pharmaceuticals (EBR:HYL) Is In A Strong Position To Grow Its Business

New minor risk - Share price stability

Forecast breakeven date moved forward to 2024

Hyloris Pharmaceuticals SA Announces U.S. FDA Approval of Maxigesic® IV

Consensus revenue estimates increase by 28%, EPS downgraded

Hyloris Pharmaceuticals SA, Annual General Meeting, Jun 04, 2024

New major risk - Revenue and earnings growth

Price target decreased by 7.1% to €19.50

Forecast breakeven date pushed back to 2025

New minor risk - Share price stability

Full year 2022 earnings released

Hyloris Pharmaceuticals SA Expands Its Pipeline with A Product Candidate for A Mineral Deficiency in the Blood (Hypophosphatemia)

Hyloris Pharmaceuticals SA Broadens Pipeline with A Nasal Product Candidate for Idiopathic Rhinitis

Price target increased to €21.00

Hyloris Pharmaceuticals SA to Report Fiscal Year 2022 Results on Apr 28, 2023

Consensus forecasts updated

Hyloris Pharmaceuticals SA to Report Fiscal Year 2022 Results on Mar 16, 2023

Hyloris Reports Positive Phase 1 Data for HY-004, A Proprietary Tranexamic Acid Oral Mouth Rinse for Bleeding Related to Dental Procedures

Hyloris Pharmaceuticals SA Receives Complete Response Letter from the US Food and Drug Administration on its Application for the US Registration of Maxigesic IV

Consensus forecasts updated

Forecast to breakeven in 2024

Price target increased to €19.50

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased to €18.75

Forecast to breakeven in 2024

Price target increased to €17.75

Hyloris Pharmaceuticals SA Announces Further Extension of Maxigesic® Iv Footprint

First half 2021 earnings released: €0.32 loss per share (vs €0.21 loss in 1H 2020)

Forecast to breakeven in 2024

Full year 2020 earnings released: €0.33 loss per share (vs €0.37 loss in FY 2019)

Revenue and earnings miss expectations

Hyloris Pharmaceuticals SA, Annual General Meeting, Jun 08, 2021

Hyloris Pharmaceuticals SA to Report First Half, 2021 Results on Aug 04, 2021

Do Institutions Own Hyloris Pharmaceuticals SA (EBR:HYL) Shares?

Hyloris and Purna Female Healthcare Announce Partnership to Develop Novel Women’s Health Product

New 90-day high: €11.90

Hyloris Pharmaceuticals SA Appoints Dietmar Aichhorn as Chief Operating Officer

First half earnings released

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin